pirtobrutinib   Click here for help

GtoPdb Ligand ID: 11628

Synonyms: BTK inhibitor 16 | Jaypirca® | LOXO-305 | LOXO305 | MCL-133 | MCL133 | RXC005
Approved drug PDB Ligand Immunopharmacology Ligand
pirtobrutinib is an approved drug (FDA & EMA (2023))
Compound class: Synthetic organic
Comment: Pirtobrutinib (LOXO-305, MCL-133) is a selective and reversible (non-covalent), oral Bruton's tyrosine kinase (BTK) inhibitor that was originally developed by LOXO oncology (now Lilly Oncology) for potential to treat B cell malignancies [3,5]. It binds within the BTK kinase pocket but its interaction does not rely on the C481 residue that is essential for the activity of earlier irreversible BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib). Therefore, it is expected to be active in cancers with wild type BTK or with C481 resistance mutations.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 125.26
Molecular weight 479.16
XLogP 4.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1ccc(cc1C(=O)NCc1ccc(cc1)c1nn(c(c1C(=O)N)N)[C@H](C(F)(F)F)C)F
Isomeric SMILES COc1ccc(cc1C(=O)NCc1ccc(cc1)c1nn(c(c1C(=O)N)N)[C@H](C(F)(F)F)C)F
InChI InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1
InChI Key FWZAWAUZXYCBKZ-NSHDSACASA-N
References
1. Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. (2022)
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Blood Cancer J, 12 (5): 80. [PMID:35595730]
2. Bond DA, Woyach JA. (2019)
Targeting BTK in CLL: Beyond Ibrutinib.
Curr Hematol Malig Rep, 14 (3): 197-205. [PMID:31028669]
3. Brandhuber BJ, Brent LT, Eary CT, Kenna A, Khan F, Renshaw VFH, Spencer SR. (2020)
Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide.
Patent number: WO2020028258A1. Assignee: Loxo Oncology, Inc.. Priority date: 31/07/2018. Publication date: 06/02/2020.
4. Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, Fenske T et al.. (2022)
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study.
Clin Lymphoma Myeloma Leuk, 22 Suppl 2: S394-S395. [PMID:36164120]
5. Iovino L, Shadman M. (2020)
Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Curr Treat Options Oncol, 21 (4): 24. [PMID:32170458]
6. Keam SJ. (2023)
Pirtobrutinib: First Approval.
Drugs, 83 (6): 547-553. [PMID:37004673]
7. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR et al.. (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet, 397 (10277): 892-901. [PMID:33676628]